山東國信(01697.HK)擬1.34億元出售泰信基金45%股權
格隆匯 12 月 14日丨山東國信(01697.HK)宣佈,於2020年12月14日,公司與控股股東魯信集團訂立股權轉讓協議,據此,根據及受限於股權轉讓協議的條款及條件,公司同意出售,而魯信集團同意收購泰信基金45%股權,代價為人民幣1.34億元。
據悉,泰信基金為一家於中國成立的有限責任公司,主要從事證券投資基金管理。
董事不時對公司的業務及運營進行戰略審查,並認為股權轉讓有利於公司優化金融股權投資佈局,專注於公司主業。此外,董事認為,股權轉讓將有助於提高公司流動性水平,強化整體財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.